Medicare Enrolled
Dr. Ishmael Jaiyesimi, D.O.
Hematology & Oncology · Royal Oak, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jaiyesimi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jaiyesimi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jaiyesimi
Dr. Ishmael Jaiyesimi is a hematology & oncology specialist in Royal Oak, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jaiyesimi performed 142,860 Medicare services across 3,686 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jaiyesimi received a total of $13,339 from 48 pharmaceutical and/or device companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jaiyesimi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in MI
$13,339 industry payments
Medicare Practice Summary
Medicare Utilization ↗142,860
Medicare services
Top 2% in MI for hematology & oncology
3,686
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~7,143 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
40,290 | $0 | $2 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
23,250 | $1 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
22,950 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 12,720 | $19 | $25 |
| Pembrolizumab injection (Keytruda) | 11,000 | $43 | $75 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
10,620 | $6 | $15 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,400 | $0 | $0 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,139 | $4 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,065 | $8 | $14 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,800 | $1 | $30 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
1,613 | $10 | $17 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,108 | $96 | $180 |
| Injection, potassium chloride, per 2 meq | 800 | $0 | $2 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
672 | $94 | $400 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
613 | $96 | $145 |
| Injection, leucovorin calcium, per 50 mg | 603 | $3 | $10 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
596 | $23 | $60 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
562 | $11 | $35 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
483 | $2 | $21 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
435 | $102 | $275 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
318 | $1 | $1 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
314 | $13 | $25 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
258 | $7 | $17 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
254 | $139 | $250 |
| Cisplatin chemotherapy injection, 10 mg Administration of a 10 mg dose of cisplatin, a chemotherapy medication, via injection. |
251 | $2 | $15 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 237 | $3 | $50 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
228 | $76 | $250 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
213 | $49 | $126 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
213 | $12 | $45 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
210 | $7 | $75 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
199 | $57 | $140 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
167 | $10 | $45 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
125 | $26 | $60 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
115 | $138 | $275 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
113 | $25 | $85 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
100 | $51 | $136 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
94 | $70 | $130 |
| New patient office visit, complex (60-74 min) | 91 | $170 | $325 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
83 | $23 | $75 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
76 | $1 | $5 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
70 | $19 | $55 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
61 | $44 | $105 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
54 | $15 | $45 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
51 | $15 | $36 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
48 | $125 | $350 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
48 | $1 | $10 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
37 | $67 | $175 |
| Mannitol 25% injection, 50 ml Administration of a 50 ml dose of 25% mannitol solution via injection. |
34 | $4 | $5 |
| Total calcium level test A blood test that measures the total amount of calcium in your body. |
23 | $5 | $5 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
22 | $6 | $7 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
18 | $8 | $12 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
16 | $15 | $40 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
45.6% high complexity
48.1% medium
6.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,339
Total received (2018-2024)
Avg $1,906/year across 7 years
Top 14% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
201
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,619 (57.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,767 (28.2%)
Other
Charitable contributions, space rental, and other categories
$1,318 (9.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$635 (4.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,097
2023
$2,723
2022
$1,047
2021
$93
2020
$25
2019
$801
2018
$6,552
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,318
Janssen Scientific Affairs, LLC
$148
Janssen Biotech, Inc.
$128
Incyte Corporation
$65
Celgene Corporation
$59
Genentech USA, Inc.
$55
Astellas Pharma US Inc
$39
PFIZER INC.
$39
Merck Sharp & Dohme LLC
$39
E.R. Squibb & Sons, L.L.C.
$39
GENZYME CORPORATION
$36
TAIHO ONCOLOGY, INC.
$26
Genmab U.S., Inc.
$26
Daiichi Sankyo Inc.
$23
Mirati Therapeutics, Inc.
$23
ARRAY BIOPHARMA INC
$18
Tempus AI, Inc
$17
Top 3 companies account for 76.0% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$6,013
Janssen Biotech, Inc.
$1,960
Novartis Pharmaceuticals Corporation
$1,716
Kite Pharma, Inc.
$458
Amgen Inc.
$254
Genentech USA, Inc.
$235
Celgene Corporation
$209
PFIZER INC.
$195
Daiichi Sankyo Inc.
$180
Janssen Scientific Affairs, LLC
$166
Pharmacyclics LLC, An AbbVie Company
$164
Coherus Biosciences Inc.
$158
GENZYME CORPORATION
$141
Foundation Medicine, Inc.
$131
E.R. Squibb & Sons, L.L.C.
$126
Astellas Pharma US Inc
$106
SANOFI-AVENTIS U.S. LLC
$100
AstraZeneca Pharmaceuticals LP
$73
Incyte Corporation
$65
GlaxoSmithKline, LLC.
$55
EMD Serono, Inc.
$54
TAIHO ONCOLOGY, INC.
$51
Merck Sharp & Dohme Corporation
$51
MorphoSys, US Inc.
$50
Genmab U.S., Inc.
$47
ARRAY BIOPHARMA INC
$46
Sumitomo Pharma America, Inc.
$42
Seagen Inc.
$39
Merck Sharp & Dohme LLC
$39
Bayer HealthCare Pharmaceuticals Inc.
$38
PharmaEssentia USA Corporation
$36
TerSera Therapeutics LLC
$35
Rigel Pharmaceuticals, Inc.
$34
Pharmacyclics LLC, an AbbVie Company
$31
TESARO, Inc.
$28
Lilly USA, LLC
$25
Mirati Therapeutics, Inc.
$23
Exelixis Inc.
$21
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Alexion Pharmaceuticals, Inc.
$19
Tempus AI, Inc
$17
Novo Nordisk Inc
$14
Shire North American Group Inc
$14
AVEO Pharmaceuticals, Inc.
$13
Kyowa Kirin, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$12
AMAG Pharmaceuticals, Inc.
$11
Clovis Oncology, Inc.
$10
Top 3 companies account for 72.6% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ALTUVIIIO · Aimovig · Alecensa · Aliqopa · Avastin · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Balversa · Bavencio · Blincyto · CABLIVI · CHANTIX · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ENHERTU · ENJAYMO · ERLEADA · Epkinly · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · KYMRIAH · Kyprolis · LONSURF · LORBRENA · LUMAKRAS · Lunsumio · MEKINIST · MONJUVI · Neulasta · NovoSeven RT · OJJAARA · OPDIVO · ORGOVYX · PADCEV · PLUVICTO · PROMACTA · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SUTENT · Stivarga · TAFINLAR · TALZENNA · TECVAYLI · Tavalisse · Trodelvy · Udenyca · VARUBI · VENCLEXTA · VYNDAQEL · Vanflyta · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · Zoladex · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (57%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
121
Per 100K population
9.5
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jaiyesimi is a mixed practice specialist, with above-average Medicare volume (top 2% in MI), with consulting-driven industry engagement in the top 14% of MI peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jaiyesimi experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Jaiyesimi performed 40,290 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jaiyesimi receive payments from pharmaceutical companies?
Yes. Dr. Jaiyesimi received a total of $13,339 from 48 companies across 201 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jaiyesimi's costs compare to other hematology & oncology specialists in Royal Oak?
Dr. Jaiyesimi's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jaiyesimi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Royal Oak
Browse hematology & oncology specialists in Royal Oak ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology